financetom
Business
financetom
/
Business
/
GE Aerospace's Slattery to step down in June, remain adviser
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GE Aerospace's Slattery to step down in June, remain adviser
Apr 10, 2024 5:34 PM

(Reuters) - The chief commercial officer of GE Aerospace, John Slattery, will step down from the jet engine maker in June and will remain an adviser, CEO Larry Culp said on Wednesday.

The Irish-born industry veteran ran the commercial arm of Brazil's Embraer, the world's third largest planemaker, before joining GE as head of its aviation business in 2020 and unveiling a new engine concept with France's Safran.

In 2022 Slattery was succeeded in the role by Culp as the over-arching GE industrial giant juggled posts in preparation for last week's historic split into three companies, with Slattery becoming chief commercial officer with an eye on strategy.

In a LinkedIn post on Wednesday, Culp hailed Slattery's "deep industry expertise and acute and strategic customer focus, which have made GE Aerospace stronger as we transformed to a standalone public company." 

Slattery, 55, said in a post that he planned to embark on a "new chapter," but did not elaborate. The banker-turned-manufacturer, who has previously been linked with senior positions at groups including Boeing or in aviation finance, could not be reached for comment.

Swedish electric airplane startup Heart Aerospace said last year it had appointed Slattery non-executive chairman, a post he is expected to keep alongside any new role after the company recently completed a funding round.

Slattery's departure from GE was announced days after it completed its breakup into three companies, marking the end of the 132-year-old conglomerate that was once the most valuable U.S. corporation and a global symbol of American business power.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
West Pharmaceutical Services Amends Credit Agreement to Establish $130 Million Incremental Term Loan
West Pharmaceutical Services Amends Credit Agreement to Establish $130 Million Incremental Term Loan
Jul 8, 2024
12:10 PM EDT, 07/08/2024 (MT Newswires) -- West Pharmaceutical Services ( WST ) said Monday it amended its existing credit agreement to establish an incremental term loan in the stated principal amount of $130 million. The loan was fully drawn at closing and matures July 2, 2027, according to a filing with the US Securities and Exchange Commission on Jul....
Why Boeing Stock Is Moving Higher Monday
Why Boeing Stock Is Moving Higher Monday
Jul 8, 2024
The Boeing Company ( BA ) shares are slightly higher on Monday after the company entered into a plea deal with the Department of Justice. What Happened: Boeing ( BA ) agreed to a plea deal with the Department of Justice where Boeing ( BA ) would plead guilty and avoid going to trial for conspiracy to defraud the United...
Why XPeng Shares Are Moving Lower Monday
Why XPeng Shares Are Moving Lower Monday
Jul 8, 2024
XPeng ( XPEV ) stock is trading lower on Monday after China’s car sales dropped in June. The Details: China’s car sales decreased by 6.9% in June compared to last year, according to Reuters. Data from the China Passenger Car Association shows that June is the third consecutive month where Chinese car sales have declined. In April car sales fell...
Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Jul 8, 2024
12:08 PM EDT, 07/08/2024 (MT Newswires) -- Defence Therapeutics ( DTCFF ) , a Canadian biopharmaceutical company, on Monday said it secured a No Objection Letter (NOL) from Health Canada for its clinical trial of its AccuTOX cancer therapy The trial allows a Phase I trial of Intratumoral Administration of ACCUM-002TM as a Monotherapy and in Combination with Opdualag in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved